Overbought Stocks
CBIO appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
CRESCENT BIOPHARMA INC (CBIO) Stock Price & Overview
NASDAQ:CBIO • KYG2545C1042
Current stock price
24.8 USD
-0.9 (-3.5%)
At close:
24.8 USD
0 (0%)
After Hours:
The current stock price of CBIO is 24.8 USD. Today CBIO is down by -3.5%. In the past month the price increased by 83.7%.
CBIO Key Statistics
1-Month Range12.979 - 27.41
Current CBIO stock price positioned within its 1-month range.
- Market Cap
- 683.488M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.74
- Dividend Yield
- N/A
CBIO Stock Performance
Today
-3.5%
1 Week
+16.54%
1 Month
+83.70%
3 Months
+93.75%
Longer-term
6 Months +95.43%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
CBIO Stock Chart
CBIO Stock Screens
CBIO currently appears in the following ChartMill screener lists.
CBIO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CBIO.
Chartmill TA Rating
Chartmill Setup Rating
CBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CBIO. No worries on liquidiy or solvency for CBIO as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CBIO Earnings
On February 26, 2026 CBIO reported an EPS of -0.54 and a revenue of 10.84M. The company beat EPS expectations (78.96% surprise) and beat revenue expectations (218.94% surprise).
Next Earnings DateN/A
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.54
Revenue Reported10.844M
EPS Surprise 78.96%
Revenue Surprise 218.94%
CBIO Forecast & Estimates
15 analysts have analysed CBIO and the average price target is 28.9 USD. This implies a price increase of 16.53% is expected in the next year compared to the current price of 24.8.
Analysts
Analysts86.67
Price Target28.9 (16.53%)
EPS Next Y63.02%
Revenue Next YearN/A
CBIO Groups
Sector & Classification
CBIO Financial Highlights
Over the last trailing twelve months CBIO reported a non-GAAP Earnings per Share(EPS) of -10.74. The EPS increased by 64.24% compared to the year before.
Income Statements
Revenue(TTM)10.84M
Net Income(TTM)-143.14M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.57% | ||
| ROE | -70.51% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%61.22%
Sales Q2Q%N/A
EPS 1Y (TTM)64.24%
Revenue 1Y (TTM)N/A
CBIO Ownership
Ownership
Inst Owners85.88%
Shares27.56M
Float25.40M
Ins Owners0.99%
Short Float %8.81%
Short Ratio10.42
CBIO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CBIO
Company Profile
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Company Info
IPO: 2014-01-10
CRESCENT BIOPHARMA INC
300 Fifth Avenue
Waltham MASSACHUSETTS 94080 US
CEO: Nassim Usman
Employees: 44
Phone: 16174305595
CRESCENT BIOPHARMA INC / CBIO FAQ
Can you describe the business of CRESCENT BIOPHARMA INC?
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
What is the current price of CBIO stock?
The current stock price of CBIO is 24.8 USD. The price decreased by -3.5% in the last trading session.
Does CBIO stock pay dividends?
CBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CBIO stock?
CBIO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of CBIO stock?
CRESCENT BIOPHARMA INC (CBIO) operates in the Health Care sector and the Biotechnology industry.
What is CRESCENT BIOPHARMA INC worth?
CRESCENT BIOPHARMA INC (CBIO) has a market capitalization of 683.49M USD. This makes CBIO a Small Cap stock.
What is the Short Interest ratio of CRESCENT BIOPHARMA INC (CBIO) stock?
The outstanding short interest for CRESCENT BIOPHARMA INC (CBIO) is 8.81% of its float.